Nov 12
Current report
6-K
Current report
PYPD · PolyPid Ltd.
Market Cap
$132.25M
Shares
21.13M
Volume · Nov 13
193.16K
Avg daily vol (3M)
123.95K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.26
Open$6.58
Day$6.03–6.58
52W close$3.58–6.60
Avg vol 30d148K
Short int447K · 2.1% of shares · 3.5d
Short vol52%
Last earningsNov 11, 2026
DataJun 2020–Nov 2026
Up next
Feb 10, 2027
Est · unconfirmed
· in 12 wks
Latest documents
2026
Oct 28
Investor event
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026
PolyPid said Deeplex 100 faces a November 28, 2026 PDUFA date, with U.S. launch expected in 2027 if approved. Its Azurdi Pharmaceuticals partnership received $30 million upfront and offers over $290 million in milestones.
Oct 28
Current report
6-K
Current report
PolyPid introduced PD01B, a Kynatrix-based doxycycline candidate for diabetic foot infections, targeting a pre-IND meeting and first-in-human study in the second half of 2027. D-PLEX₁₀₀ is under FDA Priority Review with a November 28, 2026 PDUFA goal date.
Oct 1
Current report
6-K
Current report
PolyPid’s D-PLEX₁₀₀ marketing authorization application was validated by the European Medicines Agency, initiating formal review. Its FDA Priority Review has a November 28, 2026 PDUFA goal date, and Phase 3 SHIELD II showed a 60% relative risk reduction (p=0.0013).
Oct 1
Current report
6-K
Current report
PolyPid and ADVANZ PHARMA mutually terminated their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe; exclusive European commercialization rights have reverted to PolyPid.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$31.50M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-22.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$11.95M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.1%
Year over year · more shares
Price change (1Y)
+74.9%
Trailing year
Short interest
2.1%
Latest settlement · 3.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 19.3 · elevated
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+30%
above
Price vs 50-day avg
+17%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+33%
trailing
6-month return
+29%
trailing
YTD return
+44%
this year
Relative strength
+29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
25 of 33 funds reported for Sep 30 · net -484.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.12% of shares out · ▲ +98.3% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
33 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
−57%
Y/Y
Free cash flow
$-28.1M
Balance sheet
$5.4M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+30%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
25 of 33 funds reported for Sep 30 · net -484.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.12% of shares out · ▲ +98.3% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
33 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $6 · 89%
Range high $7
vs 200-day avg +30%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PYPD
this stock
PolyPid Ltd.
|
$132.25M | +44.2% | — | — | 2.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
28
- % held
- 13.2%
- Reported
- 25 of 33
- Top holder
- AIGH Capital Management L…
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PYPD | +2.0% | +32.6% | +29.3% | +16.1% | +44.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -0.6% | +33.8% | +28.8% | +16.3% | +33.6% |
Key facts
CIK
1611842
CUSIP
M8001Q126
13F (30d)
18 filings
18 filers
Visit website
Investor relations